Risk of health-related quality of life events and pulmonary toxicities in patients with advanced neuroendocrine tumors treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.

Abstract

e16185Background: Autocrine activation of mTOR signaling pathway, mediated via insulin-like growth factor 1, was shown to involve in neuroendocrine tumor (NET) progression. Everolimus (E), an oral ...